Bosulif® (Bosutinib) - Chronic Myeloid Leukemia
Bosulif® (Bosutinib) is a third generation tyrosine kinase inhibitor. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis (cell death). Responses were seen across Bcr-Abl mutations, including those associated with dasatinib and nilotinib resistance, except T315I.
TRIALS
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
August 2017, ClinicalTrial.gov
FORUMS
Bosutinib CML Drug Development Update by LLS discussion Boards
The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia by LLS discussion Boards
VIDEOS
Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment
December 18, 2017, OBRoncology
Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML
June 5, 2017, Targeted Oncology
Dr. Shapiro Discusses Bosutinib in CML
December 23, 2013, OncLIve
Bosutinib Versus Imatinib (CML) Follow Up Study - Interview with Carlo Gambacorti-Passerini, MD, Professor of Internal Medicine
December 2011,www.oncology.tv
Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia
February 18, 2011, ecancerTV
ARTICLES
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
April 9, 2018, Dove Medical Press
Bosutinib Nears EU Approval for Frontline Ph+ CML
February 26, 2018, OncLive
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017, OncLive
Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial
December 2017, ASH 2017
Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update
December 2017, ASH 2017
Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy
December 2017, ASH 2017
Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia
December 2017, ASH 2017
Bosutinib Safe, Effective in Second and Third Line Among Patients With CML
October 27, 2017, Cancer Therapy Advisor
Trial Compares Bosutinib and Imatinib for First-Line CML Rx
September 21, 2017, Clinical Oncology News
Bosutinib Distinguishes Itself as Potential Option for Newly-Diagnosed CML
September 15, 2017, Targeted Oncology
Frontline bosutinib 'an option' for newly diagnosed CP CML
June 22, 2017, medwireNews
Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment
June 7, 2017, Cancer Therapy Advisor
Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment
April 13, 2017, PublMed
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
February 9, 2017, OncolyNurseAdvisor
Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia
December 2016, ASH 2016
Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment
December 2016, ASH 2016
Bosutinib Offers Long-Term Efficacy in CML Patients Who Failed TKI Therapy
November 23, 2016, Cancer Network
Bosutinib for CML After Progression With First-line TKI
November 10, 2016, Cancer Therapy Advisor
Long-term later-line bosutinib benefits CML patients
October 18, 2016, medwireNews
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal
Bosutinib shows 'low' vascular, cardiac event risk profile
April 21, 2016, News-Medical.net
Positive bosutinib response for elderly blast phase CML patient
January 22, 2016, News-Medical.net
Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib
December 7, 2015, ASH 2015
Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients
December 6, 2015, ASH 2015
Study Assesses Factors Influencing Bosutinib Efficacy, Safety in CML
November 5, 2015, Oncology Nurse Advisor
Bosutinib is well-suited for older patients with chronic myeloid leukemia
July 3, 2015, Medical News Today
Long-term Bosutinib in patients with chronic phase CML after prior imatinib failure
June 2015, EHA 2015
Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib
June 2, 2014, 2014 ASCO Annual Meeting
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
December 17, 2013, Journal Blood
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
January 18, 2013, Pfizer Press Releases
Bosutinib in CML Cleared for Approval in Europe
January 18, 2013, Medscape
Pfizer's Bosulif set for greater sales with EMA approval
January 18, 2013, Fierce Pharna
Pfizer, Novartis win EU nods for new leukemia, eye drugs
January 18, 2013, FierceBiotech
Bosutinib a New Option for Chronic Myeloid Leukemia
December 2012, Clinical Oncology
FDA approves orphan drug for CML
October 1, 2012, HemOnc Today
FDA Approves Bosutinib (Bosulif) for Chronic Myeloid Leukemia (CML)
September 5, 2012, Cancer Network
Bosutinib tablets for chronic myelogenous leukemia
September 5, 2012, Foodconsumer
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial.
September 4, 2012, PublMed.gov
Pfizer Wins Approval for Drug to Treat Type of Leukemia
September 4, 2012, Bloomberg
The FDA (U.S. Food and Drug Administration) approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML)
September 4, 2012, U.S. Food and Drug Administration
Mismarketed Chemical Causes Concern
May 13, 2012, The Scientist
April 9, 2018, Dove Medical Press
Bosutinib Nears EU Approval for Frontline Ph+ CML
February 26, 2018, OncLive
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017, OncLive
Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial
December 2017, ASH 2017
Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update
December 2017, ASH 2017
Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy
December 2017, ASH 2017
Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia
December 2017, ASH 2017
Bosutinib Safe, Effective in Second and Third Line Among Patients With CML
October 27, 2017, Cancer Therapy Advisor
Trial Compares Bosutinib and Imatinib for First-Line CML Rx
September 21, 2017, Clinical Oncology News
Bosutinib Distinguishes Itself as Potential Option for Newly-Diagnosed CML
September 15, 2017, Targeted Oncology
Frontline bosutinib 'an option' for newly diagnosed CP CML
June 22, 2017, medwireNews
Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment
June 7, 2017, Cancer Therapy Advisor
Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment
April 13, 2017, PublMed
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
February 9, 2017, OncolyNurseAdvisor
Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia
December 2016, ASH 2016
Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment
December 2016, ASH 2016
Bosutinib Offers Long-Term Efficacy in CML Patients Who Failed TKI Therapy
November 23, 2016, Cancer Network
Bosutinib for CML After Progression With First-line TKI
November 10, 2016, Cancer Therapy Advisor
Long-term later-line bosutinib benefits CML patients
October 18, 2016, medwireNews
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal
Bosutinib shows 'low' vascular, cardiac event risk profile
April 21, 2016, News-Medical.net
Positive bosutinib response for elderly blast phase CML patient
January 22, 2016, News-Medical.net
Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib
December 7, 2015, ASH 2015
Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients
December 6, 2015, ASH 2015
Study Assesses Factors Influencing Bosutinib Efficacy, Safety in CML
November 5, 2015, Oncology Nurse Advisor
Bosutinib is well-suited for older patients with chronic myeloid leukemia
July 3, 2015, Medical News Today
Long-term Bosutinib in patients with chronic phase CML after prior imatinib failure
June 2015, EHA 2015
Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib
June 2, 2014, 2014 ASCO Annual Meeting
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
December 17, 2013, Journal Blood
Pfizer’s Bosutinib Receives Positive Opinion For Conditional Marketing Authorization From The Committee For Medicinal Products For Human Use For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or Intolerance To Prior Therapy In Europe
January 18, 2013, Pfizer Press Releases
Bosutinib in CML Cleared for Approval in Europe
January 18, 2013, Medscape
Pfizer's Bosulif set for greater sales with EMA approval
January 18, 2013, Fierce Pharna
Pfizer, Novartis win EU nods for new leukemia, eye drugs
January 18, 2013, FierceBiotech
Bosutinib a New Option for Chronic Myeloid Leukemia
December 2012, Clinical Oncology
FDA approves orphan drug for CML
October 1, 2012, HemOnc Today
FDA Approves Bosutinib (Bosulif) for Chronic Myeloid Leukemia (CML)
September 5, 2012, Cancer Network
Bosutinib tablets for chronic myelogenous leukemia
September 5, 2012, Foodconsumer
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial.
September 4, 2012, PublMed.gov
Pfizer Wins Approval for Drug to Treat Type of Leukemia
September 4, 2012, Bloomberg
The FDA (U.S. Food and Drug Administration) approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML)
September 4, 2012, U.S. Food and Drug Administration
Mismarketed Chemical Causes Concern
May 13, 2012, The Scientist
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
April 12, 2012, PublMed
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
February 27, 2012, Journal Blood
BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO Post
Expert Point of View: BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO POST
April 12, 2012, PublMed
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
February 27, 2012, Journal Blood
BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO Post
Expert Point of View: BELA Trial Reborn: Bosutinib Produces Improved Results in Chronic Myeloid Leukemia
February 15, 2012, The ASCO POST
Faster Response Rates in CML with Bosutinib
June 15, 2011, MedscapeToday
Bosutinib Achieves Faster Response Rates in Newly Diagnosed Chronic Phase CML Patients Than Imatinib
June 3 , 2011, Monthly Prescribing Reference
STUDY 200: Study Evaluating Bosutinib in Philadelphia Chromosome Positive Leukemia
June 3, 2011, Pfizer Oncology
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
January 2011, ClinicalTrialFeeds.org
Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
December 4, 2010, Medical NewsToday
June 15, 2011, MedscapeToday
Bosutinib Achieves Faster Response Rates in Newly Diagnosed Chronic Phase CML Patients Than Imatinib
June 3 , 2011, Monthly Prescribing Reference
STUDY 200: Study Evaluating Bosutinib in Philadelphia Chromosome Positive Leukemia
June 3, 2011, Pfizer Oncology
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
January 2011, ClinicalTrialFeeds.org
Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
December 4, 2010, Medical NewsToday
